The present disclosure relates, in one aspect, to use of ghrelin splice variant or an analogue thereof for the preparation of a medicament for one or more of: treatment and/or prevention of loss of body weight and body fat, prophylaxis or treatment of cachexia, stimulation of appetite, stimulation of food intake, stimulation of weight gain, or increasingly body fat mass, or increasing body lean mass. Another aspect relates to the use of a ghrelin splice variant-like compound for the preparation of a medicament for the prophylaxis or treatment of cancer cachexia in an individual in need of such treatment. Another aspect relates to the use of a ghrelin splice variant-like compound for the preparation of a medicament for prophylaxis or treatment of cachexia in an individual by administering a subcutaneous dosage of said medicament to the individual. A further aspect relates to the use of a ghrelin splice variant-like compound or a pharmaceutically acceptable salt thereof for the preparation of a medicament for stimulation of appetite in an individual by administering a subcutaneous dosage of said medicament to the individual. A further aspect relates to a number of new ghrelin splice variant-like compounds and uses thereof, as well as to pharmaceutical compositions and medical packaging comprising the new ghrelin splice variant-like compounds.Linvention porte selon un aspect sur lutilisation dune variante ou dun analogue de la ghréline pour la préparation dun médicament présentant une ou des indications suivantes: traitement et/ou prévention de la perte de poids ou de graisse prophylaxie ou traitement de la cachexie stimulation de lappétit stimulation de lingestion daliments stimulation du gain de poids accroissement de la masse graisseuse et accroissement de la masse maigre. Selon un autre aspect, linvention porte sur lutilisation dun composé dune variante ou dun analogue de la ghréline pour préparer un médicament de prophylaxie ou traitement de la cachexie cancéreuse
